Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on pathogen reduction technology for therapeutic plasma: an overview.

B G Solheim1, J Seghatchian

  • 1Institute of Immunology, Rikshospitalet-Radiumhospitalet Medical Centre, University Hospital, University of Oslo, Oslo, Norway. bjarte.solheim@rikshospitalet.no

Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis
|August 29, 2006
PubMed
Summary

Pathogen reduction technologies (PRT) for therapeutic plasma improve viral safety but can affect protein quality. Current methods vary in effectiveness and require further clinical evaluation for interchangeability and adequacy of standards.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2020
Same author

WITHDRAWN: Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2020
Same author

NEW HORIZONS ON STEM CELL CRYOPRESERVATION THROUGH THE ARTIFICIAL EYES OF CD 34+, USING MODERN FLOW CYTOMETRY TOOLS.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2020
Same author

Corrigendum to "Reflections on the usefulness of extracorporeal photopheresis in renal transplant rejection: A concise review of the involved mechanisms and therapeutic perspectives" [Transfus. Apher. Sci. 57 (February (1)) (2018) 115-117].

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2018
Same author

Implementing a patient blood management program in Norway: Where to start?

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2016
Same author

Implementation of a standardised method for the production of allogeneic serum eye drops from regular blood donors in a Norwegian University Hospital: Some methodological aspects and clinical considerations.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2015

Area of Science:

  • Blood banking and transfusion medicine
  • Biotechnology and bioprocessing
  • Infectious disease control

Background:

  • Therapeutic plasma requires optimal viral safety and coagulation factor levels for clinical efficacy.
  • Emerging pathogen reduction technologies (PRT) for plasma are undergoing clinical evaluation.
  • Existing PRT methods have limitations in pathogen inactivation spectrum and potential effects on plasma quality.

Purpose of the Study:

  • To provide an update on three photoactive PRT targeting nucleic acids for single-unit fresh-frozen plasma (FFP).
  • To review experiences with classical pathogen reduction of pooled plasma using solvent-detergent (SD) treatment.
  • To highlight differences in PRT efficacy, plasma quality impact, and adverse reaction profiles.

Main Methods:

Related Experiment Videos

  • Overview of photoactive PRT: Methylene Blue Light Treated (MBLT), Psoralen Light Treated (PLT), and Riboflavin Light Treated (RLT) plasma.
  • Review of Solvent/Detergent (SD) treated pooled plasma.
  • Discussion of additional purification steps (e.g., oil extraction, chromatography) to remove chemical residues.

    • Main Results:

    • Pooled SD-plasma is the most clinically documented PRT product, followed by MBLT-plasma.
    • PLT-plasma is CE-marked in Europe; RLT-plasma is under development.
    • No current PRT method inactivates all pathogens; all impact plasma quality to some extent compared to FFP.

    Conclusions:

    • PRT methods differ in pathogen reduction capabilities, effects on plasma protein activity, and safety profiles.
    • Additional purification steps are necessary for photoactive PRT to improve safety margins.
    • Further clinical trials are needed to determine the interchangeability of PRT plasma products and adequacy of FFP standards.